ArticleActa neuropathologica communications2018
Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.
Article in Acta neuropathologica communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 37 citations in OpenAlex.
- Is there a link between multiple sclerosis and Alzheimer disease? A critical note.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Ligands for Protein Fibrils of Amyloid-β, α-Synuclein, and Tau.Chemical reviews · 2025Review
- Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.Molecular neurodegeneration · 2025Review
- Microscopy assessment of a fluorescence [Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease.Acta neuropathologica · 2024Article
- Affection of Motor Network Regions by Tau Pathology Across the Alzheimer's Disease Spectrum.eNeuro · 2024Article
- Imaging of Tauopathies with PET Ligands: State of the Art and Future Outlook.Diagnostics (Basel, Switzerland) · 2023Review
- ATN profile classification across two independent prospective cohorts.Frontiers in medicine · 2023Article
- Plasma Biomarkers of Alzheimer's Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice.Journal of Alzheimer's disease reports · 2023Review
- Article
- Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET.European journal of nuclear medicine and molecular imaging · 2022Article
- 18F-MK-6240 tau-PET in genetic frontotemporal dementia.Brain : a journal of neurology · 2022Article
- Perivascular spaces as a potential biomarker of Alzheimer's disease.Frontiers in neuroscience · 2022Review
- Changes in the language system as amyloid-β accumulates.Brain : a journal of neurology · 2021Article
- Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective.International journal of molecular sciences · 2021Review
- Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease.Brain : a journal of neurology · 2021Article
- Tau strains shape disease.Acta neuropathologica · 2021Review
- Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia.Frontiers in aging neuroscience · 2021Review
- Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue forFrontiers in neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imaging of pathological tau with positron emission tomography (PET) has the potential to allow early diagnosis of the dementias and monitoring of disease progression, including assessment of therapeutic interventions, in vivo. The first generation of tau PET tracers, including the carbazole flortaucipir and the 2-arylquinolines of the THK series, are now used in clinical research; however, concerns have been raised about off-target binding and low sensitivity.With the aim to determine the nature of tau pathology depicted by structurally distinct tau ligands we carried out a microscopic neuropathological evaluation in post-mortem human brain tissue of cases with primary and secondary tauopathies. Carbazole and 2-arylquinoline binding was only observed in cases with Alzheimer's disease and one case with frontotemporal dementia and parkinsonism linked to chromosome 17 exhibiting a R406W MAPT mutation. In end stage Alzheimer's disease cases, fluorescent imaging with the carbazole T726 and the 2-arylquinoline THK-5117 revealed high inter- and intra-case variability of tracer binding, and this was corroborated by quantitative phosphorimaging with the PET tracer [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.